co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
ZyCov-D is a needle-free three-dose vaccine. The three doses of the jab are to be administered 28 days apart
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Pimavanserin tablets in strength of 10 mg, Zydus Cadila said in a statement.
Zydus Cadila, in accordance with the Centre's order, is expected to supply a total of one crore ZyCov-D doses to the central government by end of this month.
The company has received final approval from the US Food and Drug Administration (USFDA) to Decitabine for Injection in the strength of 50 mg/vial single-dose vial, Zydus Cadila said in a statement.
The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a generic version of Arranon injection.
Union Health Minister Mansukh Mandaviya on Thursday said the government does not want to make haste about administering COVID vaccines to children and any decision in this regard will be taken based on expert opinion.
ZyCov-D will be administered using a needle-free applicator, called PharmaJet, instead of traditional syringes.
The Ahmedabad-based pharma company earlier had proposed a price of Rs 1,900 for its three-dose regimen, a source had said.
The drug regulator had in August given Emergency Use Authorisation to the three-dose vaccine for everyone above the age of 12.
The company's US-based subsidiary Zydus Pharmaceuticals (USA) Inc has received final approval from the US Food and Drug Administration (USFDA) to market Apremilast tablets in the strengths of 10 mg, 20 mg, 30 mg in the US market, Zydus Cadila said in a statement.
The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Brexpiprazole tablets in the strength of 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, the drug firm said in a statement.
The company said its subsidiary has received tentative approval from the United States Food and Drug Administration (FDA) for its new drug application for Sitagliptin base 25, 50 and 100 mg tablets.
India has approved the world’s first plasmid DNA vaccine, ZyCoV-D, for Emergency Use Authorization (EUA). Wondering how the vaccine works? Here's all you need to know.
When asked about side effects of the vaccine, Group MD Sharvil Patel said trials were conducted for 2,800 volunteers including 1,400 adolescents aged 12-18 years and no severe side effects related to the vaccine were seen.
The Drug Controller General of India's subject expert committee has called for additional data for the company's two-dose vaccine
Zydus Cadila's jab will be the sixth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V, Moderna and J&J.
Fulvestrant injection is used alone or in combination with other drugs to treat a certain type of hormone receptor positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body in women who have experienced menopause.
If approved, Zydus Cadila's jab will be the fifth COVID-19 vaccine to get approved in India after Covishield, Covaxin, Sputnik V and Moderna.
Managing Director of Zydus Group Sharvil Patel says the company has invested Rs. 400-500 crore for the development of ZyCoV-D, the world’s first plasmid DNA vaccine for human use.
The company has received final approval from the United States Food and Drug Administration (USFDA) to market Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 100 mg/150 mg, 133 mg/200 mg and 167 mg/250 mg, Zydus Cadila said in a statement.
Zydus Cadila conducted trials of ZyCoV-D at 50 sites spread across the country, making it the largest such trial in the country. It is also the first COVID vaccine in India to be tested among the 12-18 age group
The Centre said that a total of 51.6 crore COVID-19 vaccine doses would be made available by July 31 of which 35.6 crore have already been provided.
The Ahmedabad-based drug maker has received approval from the US Food and Drug Administration (USFDA) for the injection in the strengths of 100mg/vial, 500 mg/vial, and 1000 mg/vial, single-dose vials, Zydus Cadila said in a statement.
Zydus Cadila has received tentative approval from the US Food and Drug Administration (USFDA) to market Brivaracetam tablets, in the strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg, Cadila Healthcare said in a regulatory filing.
The antibody cocktail therapy is most suited for high-risk COVID-19 patients within the first 10 days of onset of symptoms and meet any of the listed criteria such as age being 65 years or above.
